US to Test Medicare and Medicaid Coverage for Weight-Loss Drugs
TL;DR Summary
A proposed Trump administration plan to allow Medicare and Medicaid to cover obesity drugs like Lilly's Zepbound and Novo's Wegovy could benefit these companies, but high list prices remain a significant barrier. The plan's details are unclear, and cost concerns persist, with estimates suggesting substantial increases in federal spending if coverage expands. The move could improve access for many obese patients but faces skepticism from investors due to potential cost implications.
- Trump’s Weight-Loss Experiment Could Aid Lilly, Novo. Cost Is Still a Problem. Barron's
- Medicare, Medicaid plan to experiment with covering weight loss drugs The Washington Post
- US plans to test Medicare, Medicaid coverage for weight-loss drugs, Washington Post reports Reuters
- Trump officials plan coverage for weight loss drugs under Medicare and Medicaid theguardian.com
- Medicare, Medicaid to try coverage of GLP-1s for obesity, report says Axios
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
3 min
vs 4 min read
Condensed
90%
723 → 71 words
Want the full story? Read the original article
Read on Barron's